Table 3.

Backward stepwise elimination mixed effect models predicting MUTT-II pre-specified outcomes with day-6 culture positivity (yes/no), controlling for treatment arm, organism, enrollment clinical characteristics. Covariates listed are what remained in the best fit model. P_adj values for our variable of interest, “6-day culture positivity” was corrected using a permutation p-value and shown in last column

Covariate	Coefficient	95% Confidence Interval	P	Padj
Cox proportional hazards model predicting perforation or need for TPK, N =190
Culture positive at day 6 (vs. negative)	1.99	(1.28 to 3.08)	0.002	0.013
Enrollment Infiltrate/scar-size	1.31	(1.14 to 1.51)	<0.001
Enrollment Depth	1.50	(1.09 to 2.05)	0.01
Organism (Aspergillus vs. Fusarium)	0.63	(0.39 to 1.04)	0.07
Enrollment Hypopyon (yes vs. no)	1.56	(0.92 to 2.64)	0.10
Oral Voriconazole (vs. Oral Placebo)	0.75	(0.50 to 1.24)	0.16	33
Multiple linear regression predicting 3-month BSCVA (logMAR), N=162
Culture positive at day 6 (vs. negative)	0.26	(0.10 to 0.42)	0.001	0.004
Enrollment BSCVA	0.56	(0.30 to 0.81)	<0.001
Enrollment Infiltrate/scar-size	0.11	(0.06 to 0.17)	<0.001
Enrollment Depth	−0.23	(−0.39 to −0.07)	0.01
Enrollment Hypopyon (yes vs. no)	0.15	(−0.04 to 0.34)	0.12
Multiple linear regression predicting 3-month infiltrate/scar (mm), N=170
Culture positive at day 6 (vs. negative)	−0.24	(−0.86 to 0.38)	0.45	0.46
Enrollment Infiltrate/scar-size	0.73	(0.54 to 0.91)	<0.001
Enrollment Hypopyon (yes vs. no)	0.74	(0.08 to 1.39)	0.03
Oral Voriconazole (vs. Oral Placebo)	−0.57	(−1.15 to 0.01)	0.054
Cox proportional hazards model predicting time to reepithelialization, N=190
Culture positive at day 6 (vs. negative)	0.77	(0.46 to 1.28)	0.31	0.38
Baseline epithelial defect size	0.59	(0.50 to 0.71)	<0.001
Enrollment Depth	0.73	(0.50 to 1.06)	0.10
Organism (Other species vs. Fusarium)	0.67	(0.40 to 1.14)	0.14